Naveen Pemmaraju, MD of the MD Anderson Cancer Center, Houston, TX explains an ongoing Phase II clinical trial of LCL16 in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF) or post-essential thrombocytosis myelofibrosis (post-ET MF) (NCT02098161). LCL161 is a SMAC mimetic and antagonist of the inhibitor of apoptosis protein, and used for the first time for patients with these rare disorders in this study. Initial results have been encouraging, and the plan is to continue enrolling. Dr Naveen points to the possibility of immune system side effects. Recorded at Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates